ClinicalTrials.gg
Sign In
Biological

Melanoma-Associated Antigen 3 clinical trials

Includes 7 studies of Melanoma-associated antigen 3.

studies test it
7
open now
0
in phase 3
1
first study started
1997

How each study uses Melanoma-Associated Antigen 3 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

Studies by the year they started

7 studies that test it; most in 2005 (2)

Studies that test Melanoma-Associated Antigen 3, by start year
YearStudies
19971
20021
20031
20041
20052
20111

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
6
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Melanoma
5
Squamous Cell Carcinoma of Head and Neck
1
Multiple Myeloma
1

Who runs them

Industry 0 · Other 7

M.D. Anderson Cancer Center (2) · University of Chicago (2) · University of Maryland, Baltimore (1) · University of Arkansas (1) · Charite University, Berlin, Germany (1)

Often tested with

Tested in the same studies.

Astuprotimut-r (3) · Interleukin-2 (2) · HPV16 Vaccine (1) · Interleukin-12 (1) · MART-1 Antigen (1) · GP-100 antigen (1) · Melanocyte Protein PMEL (1) · NA17 (1)

Studies

Open first, then newest update. How each study uses Melanoma-Associated Antigen 3 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Given beside what is tested · 3 — Melanoma-Associated Antigen 3 is usual care or a partner of the new treatment